APA (7th ed.) Citation

Azad, A., Fizazi, K., Matsubara, N., Saad, F., De Giorgi, U., Joung, J. Y., . . . Agarwal, N. (2024). Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. European journal of cancer, 213, . https://doi.org/10.1016/j.ejca.2024.115078

Chicago Style (17th ed.) Citation

Azad, Arun, et al. "Talazoparib Plus Enzalutamide in Metastatic Castration-resistant Prostate Cancer: Safety Analyses from the Randomized, Placebo-controlled, Phase III TALAPRO-2 Study." European Journal of Cancer 213 (2024). https://doi.org/10.1016/j.ejca.2024.115078.

MLA (9th ed.) Citation

Azad, Arun, et al. "Talazoparib Plus Enzalutamide in Metastatic Castration-resistant Prostate Cancer: Safety Analyses from the Randomized, Placebo-controlled, Phase III TALAPRO-2 Study." European Journal of Cancer, vol. 213, 2024, https://doi.org/10.1016/j.ejca.2024.115078.